Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chon, Young Eun | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Kim, Mi Na | - |
dc.contributor.author | Roh, Yun Ho | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.date.accessioned | 2021-10-01T07:40:09Z | - |
dc.date.available | 2021-10-01T07:40:09Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.issn | 1440-1746 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54328 | - |
dc.description.abstract | Background and Aim Antiviral therapy (AVT) induces fibrosis regression in patients with chronic hepatitis B. We investigated long-term effects of entecavir (ETV) versus tenofovir (TDF) on fibrotic burden. Methods Treatment-naïve chronic hepatitis B patients who had begun ETV or TDF were recruited from four tertiary hospitals. The aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) were used to determine fibrotic burden. Results In the entire population (n = 3277), although patients treated with ETV had higher baseline APRI (1.71 vs 1.07, P < 0.001) and FIB-4 (3.60 vs 2.80, P < 0.001) than those treated with TDF, significant fibrosis regression was identified during 6 years of AVT in both ETV (APRI, mean 1.71 → 0.48, P < 0.001; FIB-4, mean 3.60 → 2.21, P < 0.001) and TDF groups (APRI, mean 1.07 → 0.43, P < 0.001; FIB-4, mean 2.80 → 2.19, P < 0.001). In patients without cirrhosis (n = 2366), baseline APRI was significantly higher in ETV group than in TDF group (1.72 vs 0.97, P < 0.001); however, they became similar after 6 months. Similarly, baseline FIB-4 was significantly higher in ETV group than in TDF group (3.25 vs 2.35, P < 0.001), but became similar from 4 to 6 years. In patients with cirrhosis (n = 911), baseline APRI (1.70 vs 1.34, P < 0.001) and FIB-4 (4.62 vs 3.91, P = 0.005) were higher in ETV group than in TDF, however, both parameters became statistically similar from 6 months to 6 years. Conclusion Significant regression of APRI and FIB-4 was observed during long-term ETV and TDF treatment. Despite higher baseline fibrotic burden in ETV group, fibrotic burden between the groups eventually converged through significant fibrosis regression after 1 to 4 years of AVT. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jgh.15678 | - |
dc.identifier.scopusid | 2-s2.0-85114880690 | - |
dc.identifier.wosid | 000695908600001 | - |
dc.identifier.bibliographicCitation | Journal of Gastroenterology and Hepatology, v.37, no.1, pp 200 - 207 | - |
dc.citation.title | Journal of Gastroenterology and Hepatology | - |
dc.citation.volume | 37 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 200 | - |
dc.citation.endPage | 207 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SIMPLE NONINVASIVE INDEX | - |
dc.subject.keywordPlus | PLATELET RATIO INDEX | - |
dc.subject.keywordPlus | LIVER FIBROSIS | - |
dc.subject.keywordPlus | ASPARTATE-AMINOTRANSFERASE | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MARKERS | - |
dc.subject.keywordPlus | FIB-4 | - |
dc.subject.keywordAuthor | APRI | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | FIB-4 | - |
dc.subject.keywordAuthor | Fibrosis | - |
dc.subject.keywordAuthor | Tenofovir | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.